Capricor Therapeutics (NASDAQ:CAPR) Rating Lowered to “Strong Sell” at Wall Street Zen

Capricor Therapeutics (NASDAQ:CAPR) was downgraded by Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued to investors on Saturday.

A number of other research firms also recently commented on CAPR. HC Wainwright restated a “neutral” rating on shares of Capricor Therapeutics in a research report on Monday, July 27th. LADENBURG THALM/SH SH cut Capricor Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday. Oppenheimer reissued a “market perform” rating on shares of Capricor Therapeutics in a research report on Monday, July 27th. Cantor Fitzgerald lowered shares of Capricor Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.50 price objective on the stock. in a report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Monday, June 15th. Ten analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $29.15.

Capricor Therapeutics Price Performance

Shares of NASDAQ CAPR opened at $3.85 on Friday. The company has a market capitalization of $222.95 million, a P/E ratio of -1.66 and a beta of 0.54. The company has a 50 day simple moving average of $23.00 and a 200-day simple moving average of $26.79. Capricor Therapeutics has a 1 year low of $2.96 and a 1 year high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). As a group, research analysts expect that Capricor Therapeutics will post -1.62 EPS for the current year.

Insider Transactions at Capricor Therapeutics

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 24,100 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $30.38, for a total transaction of $732,158.00. Following the transaction, the chief financial officer directly owned 11,223 shares in the company, valued at $340,954.74. This represents a 68.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 25,000 shares of company stock valued at $759,158 over the last 90 days. 9.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Suvretta Capital Management LLC acquired a new position in Capricor Therapeutics during the 4th quarter worth about $51,533,000. Tang Capital Management LLC acquired a new position in Capricor Therapeutics in the 4th quarter valued at about $49,062,000. RA Capital Management L.P. purchased a new stake in Capricor Therapeutics during the fourth quarter worth about $43,516,000. Darwin Global Management Ltd. purchased a new stake in Capricor Therapeutics during the fourth quarter worth about $23,168,000. Finally, SB Capital Management Inc acquired a new stake in shares of Capricor Therapeutics during the fourth quarter worth about $11,544,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Key Stories Impacting Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Neutral Sentiment: The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3 that available evidence did not support Deramiocel’s effectiveness. The vote is non-binding, so the FDA could still reach a different decision, but it is a significant setback for Capricor’s regulatory path. Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
• Neutral Sentiment: FDA briefing materials and media reports questioned whether Deramiocel met its pre-specified cardiac endpoint and challenged Capricor’s interpretation of Phase 3 results. The dispute centers on changes to the statistical analysis plan that allegedly were not agreed to by the FDA before the company resubmitted its biologics license application. Capricor plummets after FDA panel votes against Duchenne heart disease therapy
• Negative Sentiment: Multiple law firms have announced securities-fraud investigations or filed shareholder class actions alleging that Capricor made materially misleading statements or failed to disclose regulatory and clinical-data risks related to Deramiocel. The lawsuits add legal, financial and reputational risk, although the allegations have not been proven. Investors have been encouraged to contact the firms, with some notices citing a September 28, 2026 deadline. CAPR Investor Alert: Class Action Lawsuit Filed on Behalf of Capricor Therapeutics Investors
• Negative Sentiment: Analysts responded by cutting ratings, including downgrades from Cantor Fitzgerald, Maxim Group, Ladenburg Thalmann and Alliance Global Partners. Cantor moved to Neutral with a $3.50 price target, while JonesTrading reaffirmed a Hold rating. Capricor Therapeutics downgraded by Cantor Fitzgerald

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.